Current Treatment Options in Oncology最新文献

筛选
英文 中文
Precision Adjuvant Therapy in Gastrointestinal Stromal Tumor: Adjuvant-Specific Evidence Versus Metastatic Extrapolation. 胃肠道间质瘤的精确辅助治疗:佐剂特异性证据与转移性推断。
IF 5.8 2区 医学
Current Treatment Options in Oncology Pub Date : 2026-11-14 DOI: 10.1007/s11864-026-01419-8
Wen-Kuan Huang, Shang-Yu Wang, Chun-Nan Yeh
{"title":"Precision Adjuvant Therapy in Gastrointestinal Stromal Tumor: Adjuvant-Specific Evidence Versus Metastatic Extrapolation.","authors":"Wen-Kuan Huang, Shang-Yu Wang, Chun-Nan Yeh","doi":"10.1007/s11864-026-01419-8","DOIUrl":"10.1007/s11864-026-01419-8","url":null,"abstract":"<p><strong>Opinion statement: </strong>For a patient with a resected gastrointestinal stromal tumor, we base adjuvant decisions on evidence produced after surgery rather than on findings extrapolated from advanced disease. Genotyping comes first, because it identifies the patients who should not receive imatinib: tumors driven by the PDGFRA D842V mutation, succinate dehydrogenase-deficient tumors, and neurofibromatosis type 1-associated tumors do not respond to imatinib, and these patients are spared an ineffective drug. For imatinib-sensitive tumors judged to be at high risk of recurrence by the modified National Institutes of Health or Armed Forces Institute of Pathology criteria, we offer adjuvant imatinib at 400 mg daily for three years, the schedule tested in randomized adjuvant trials. We do not routinely escalate to 800 mg daily for tumors with a KIT exon 9 mutation in the adjuvant setting. The advantage of the higher dose was shown in advanced disease, and the adjuvant cohorts that have examined this question found no benefit from dose escalation after resection. We therefore treat exon 9 dosing as unresolved and discuss the uncertainty with the patient. When the risk of recurrence is highest, we raise the option of continuing imatinib beyond three years and explain that longer treatment delays relapse but has not been shown to cure the disease or prolong survival. Post-resection circulating tumor DNA testing is under study and is not yet part of routine care. We also consider prognostic factors that current risk schemes leave out, and we weigh genotype, clinicopathological risk, and emerging molecular markers together because none of them settles the decision on its own. Within the high-risk group we individualize treatment and offer a clinical trial whenever one is available.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13769689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy for Adult-Type Diffuse WHO Grade 2 Gliomas in the Era of IDH Inhibition: A Narrative Review. 在IDH抑制时代,成人型弥漫性WHO 2级胶质瘤的放疗:一个叙述性的回顾。
IF 5.8 2区 医学
Current Treatment Options in Oncology Pub Date : 2026-11-07 DOI: 10.1007/s11864-026-01425-w
Alper Kahvecioglu, Gozde Yazici
{"title":"Radiotherapy for Adult-Type Diffuse WHO Grade 2 Gliomas in the Era of IDH Inhibition: A Narrative Review.","authors":"Alper Kahvecioglu, Gozde Yazici","doi":"10.1007/s11864-026-01425-w","DOIUrl":"10.1007/s11864-026-01425-w","url":null,"abstract":"<p><strong>Opinion statement: </strong>Managing adult-type diffuse WHO grade 2 gliomas requires moving beyond classical histological evaluation to rely on an integrated molecular profile and individualized risk assessment. Treatment decisions must be carefully tailored to the biological behavior of the tumor. For patients with aggressive molecular features, significant residual tumor volume, or rapid clinical progression, the primary objective is to achieve robust and durable disease control. In this patient group, postoperative radiotherapy (RT) combined with alkylating chemotherapy remains the standard approach supported by the strongest long-term survival data. Despite modern advances in targeted therapies, RT remains a cornerstone of treatment. Conversely, for clinically stable patients with favorable characteristics, immediate RT can be safely deferred. In this population, the IDH inhibitor vorasidenib offers a practice-changing clinical alternative to active surveillance, significantly prolonging progression-free survival while preserving quality of life. Ultimately, treatment decisions must be individualized through a multidisciplinary approach that accounts for molecular biomarkers, the extent of surgical resection, and the clinical status of the patient.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149372082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synergizing Short-Course Radiotherapy with Immunotherapy in Locally Advanced Rectal Cancer: Current Evidence, Challenges, and Future Directions. 局部晚期直肠癌的短期放疗与免疫治疗协同:目前的证据、挑战和未来的方向。
IF 5.8 2区 医学
Current Treatment Options in Oncology Pub Date : 2026-11-05 DOI: 10.1007/s11864-026-01424-x
Lemeng Xu, Ye Jiao, Yongchang Wei, Min Luo
{"title":"Synergizing Short-Course Radiotherapy with Immunotherapy in Locally Advanced Rectal Cancer: Current Evidence, Challenges, and Future Directions.","authors":"Lemeng Xu, Ye Jiao, Yongchang Wei, Min Luo","doi":"10.1007/s11864-026-01424-x","DOIUrl":"10.1007/s11864-026-01424-x","url":null,"abstract":"<p><strong>Opinion statement: </strong>The management of locally advanced rectal cancer is increasingly moving beyond a uniform cytotoxic framework toward biomarker-informed multimodal treatment. Short-course radiotherapy (SCRT) is an established and convenient radiotherapy option and may also provide an immunomodulatory context for immune checkpoint blockade. Preclinical evidence suggests that hypofractionated radiotherapy can promote immunogenic cell death and modulate the tumor immune microenvironment; however, whether the fractionation schedule of SCRT provides a clinically meaningful immunological advantage over long-course chemoradiotherapy remains uncertain. Early randomized studies of SCRT-based chemoimmunotherapy in predominantly proficient mismatch repair/microsatellite-stable (pMMR/MSS) populations have reported encouraging improvements in pathological or overall complete response rates compared with their respective control regimens. Nevertheless, differences in comparator arms, chemotherapy exposure, immunotherapy schedules, endpoint definitions, and follow-up duration preclude firm conclusions regarding the optimal radiotherapy backbone or long-term survival benefit. These findings support further prospective evaluation of SCRT-based combinations and response-adapted non-operative management in appropriately selected patients. Longitudinal circulating tumor DNA, multi-omics profiling, MR-guided adaptive radiotherapy, and computational models such as \"digital twins\" may contribute to improved patient selection and surveillance, but their clinical utility requires prospective validation.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing CLDN18.2-Targeted Therapies in Pancreatic Cancer: Current Clinical Development and Therapeutic Opportunities. 推进胰腺癌cldn18.2靶向治疗:目前的临床发展和治疗机会
IF 5.8 2区 医学
Current Treatment Options in Oncology Pub Date : 2026-11-04 DOI: 10.1007/s11864-026-01423-y
Huanxin Yan, Xiaoli Shi
{"title":"Advancing CLDN18.2-Targeted Therapies in Pancreatic Cancer: Current Clinical Development and Therapeutic Opportunities.","authors":"Huanxin Yan, Xiaoli Shi","doi":"10.1007/s11864-026-01423-y","DOIUrl":"10.1007/s11864-026-01423-y","url":null,"abstract":"<p><strong>Opinion statement: </strong>Pancreatic cancer (PC) continues to pose a major clinical challenge due to its aggressive nature and poor response to conventional treatments. CLDN18.2 (Claudin 18.2), a tight junction protein with highly restricted normal tissue expression, is frequently aberrantly expressed in PC, rendering it an attractive candidate for targeted therapy. The recent approval of zolbetuximab in CLDN18.2-positive gastric/gastroesophageal junction cancer has driven the exploration of CLDN18.2-targeted agents in PC. This review comprehensively summarizes the current landscape of CLDN18.2-targeted agents in PC, encompassing monoclonal antibodies, bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cell (CAR-T) therapies. Although early-phase studies have shown encouraging clinical activity in patients with high CLDN18.2 expression, several challenges remain, including treatment-related toxicities, tumor heterogeneity, mechanisms of resistance, and biomarker-guided patient selection. Future efforts will focus on multispecific antibodies, combination strategies, personalized therapies, and expanded applications in other CLDN18.2-positive malignancies. Overall, CLDN18.2-targeted therapies represent a rapidly progressing field with significant potential to improve survival outcomes in PC.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Management and Risk Stratification of Retroperitoneal Sarcoma with a Focus on Locally Recurrent Disease. 腹膜后肉瘤的临床管理和风险分层,重点是局部复发性疾病。
IF 5.8 2区 医学
Current Treatment Options in Oncology Pub Date : 2026-11-03 DOI: 10.1007/s11864-026-01418-9
Ryan D Watkins, Lee D Cranmer, Sagus Sampath, Adam G Rock, Bridget N Fahy, William W Tseng
{"title":"Clinical Management and Risk Stratification of Retroperitoneal Sarcoma with a Focus on Locally Recurrent Disease.","authors":"Ryan D Watkins, Lee D Cranmer, Sagus Sampath, Adam G Rock, Bridget N Fahy, William W Tseng","doi":"10.1007/s11864-026-01418-9","DOIUrl":"10.1007/s11864-026-01418-9","url":null,"abstract":"<p><strong>Opinion statement: </strong>Retroperitoneal sarcomas are a group of rare malignancies comprised of several histological types, each carrying a unique risk of local recurrence and metastatic potential. In primary disease, surgery remains the mainstay of treatment and is the best opportunity for cure. In recurrent disease, treatment algorithms are less well defined. Surgery, radiation, systemic therapy, and in select cases, observation can be considered for management of recurrent disease. Histologic type drives a significant portion of clinical decision-making but incorporating all relevant clinicopathological data is important. To guide selection and timing of treatment, patients should undergo risk stratification. Nomograms and risk calculators are available to facilitate this. Experience and clinical judgement remain paramount. In the future, deeper molecular and radiologic characterization may further optimize decision-making in these challenging cases.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13727862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149327078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current Role of Radiomics for Management of Soft Tissue Sarcoma. 放射组学在软组织肉瘤治疗中的作用。
IF 5.8 2区 医学
Current Treatment Options in Oncology Pub Date : 2026-10-29 DOI: 10.1007/s11864-026-01420-1
Yu-Cherng Chang, Nora McGowan, Francesco Alessandrino, Etan Dayan, Emily Jonczak, Brooke Crawford, Nasir Ud Din, Ty Subhawong
{"title":"Current Role of Radiomics for Management of Soft Tissue Sarcoma.","authors":"Yu-Cherng Chang, Nora McGowan, Francesco Alessandrino, Etan Dayan, Emily Jonczak, Brooke Crawford, Nasir Ud Din, Ty Subhawong","doi":"10.1007/s11864-026-01420-1","DOIUrl":"10.1007/s11864-026-01420-1","url":null,"abstract":"<p><strong>Opinion statement: </strong>Soft tissue sarcomas represent a diverse set of malignancies with equally diverse behavior, ranging from relatively indolent low-grade tumors to aggressive high-grade tumors with high metastatic potential. Initial diagnosis hinges on tissue biopsy for determining histologic subtype and grade, while conventional imaging plays critical roles in defining local tumor size and extent, staging, treatment response, and disease surveillance. However, conventional semantic interpretation of imaging studies overlooks much of the complex imaging data embedded in routine clinical studies. Radiomics encompasses the identification of novel disease biomarkers extracted from highly quantitative characterizations of tumor structure and heterogeneity and has shown promise in providing a deeper understanding of soft tissue sarcomas. Given the increasing usage of imaging in soft tissue sarcomas, particularly usage of MRI, it behooves both clinicians and radiologists to further the depth of understanding that may be gleaned from radiomics. These insights, although primarily experimental, represent a rapidly evolving landscape in soft tissue sarcoma diagnosis and management where radiomics will be increasingly integrated into clinical practice. The present work focuses on the latest updates with regards to the application of radiomics to the diagnosis, prediction of treatment response, assessment of treatment response, and prognosis of soft tissue sarcomas and how they may affect sarcoma management.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149301441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Image-Guided Ablative Options for Desmoid Fibromatosis: Contemporary Evidence and Guideline Integration. 图像引导下硬纤维瘤病的消融选择:当代证据和指南整合。
IF 5.8 2区 医学
Current Treatment Options in Oncology Pub Date : 2026-10-28 DOI: 10.1007/s11864-026-01422-z
Daniel A Adamo, John J Schmitz, Tasha L Welch, Thomas D Atwell, Brittany L Siontis, Brian T Welch
{"title":"Image-Guided Ablative Options for Desmoid Fibromatosis: Contemporary Evidence and Guideline Integration.","authors":"Daniel A Adamo, John J Schmitz, Tasha L Welch, Thomas D Atwell, Brittany L Siontis, Brian T Welch","doi":"10.1007/s11864-026-01422-z","DOIUrl":"10.1007/s11864-026-01422-z","url":null,"abstract":"<p><strong>Opinion statement: </strong>Most patients with a newly diagnosed desmoid tumor should begin with multidisciplinary evaluation and active surveillance rather than immediate intervention, provided that symptoms are limited and further growth is unlikely to create irreversible morbidity. Treatment should be initiated when pain, functional limitation, sustained progression, or threatened critical structures make continued observation unacceptable. Percutaneous cryoablation is generally favored because the ice ball can be monitored directly, treatment can be personalized/tailored with the synergistic benefit of multiple probes, and the procedure can be repeated or staged when a complete margin would be unsafe. Complete ablation should be targeted when the entire tumor can be covered without jeopardizing skin, nerves, bowel, or other vulnerable structures; deliberate subtotal ablation is appropriate when the principal goal is pain relief or functional improvement and a safe circumferential margin is not achievable. Hydrodissection, skin warming, neural protection, and conservative treatment near critical anatomy are essential. Magnetic resonance-guided focused ultrasound is an attractive incisionless alternative for tumors with a favorable acoustic window. Microwave or radiofrequency ablation should be reserved for carefully selected lesions and experienced operators; electrochemotherapy and chemical ablation remain investigational with some promising early evidence. Embolization can be useful for hypervascular tumors that are poorly suited to direct percutaneous treatment. Local and systemic therapy should not be viewed as mutually exclusive: systemic treatment is often preferable for diffuse, intra-abdominal, or anatomically hazardous disease, while ablation can address a dominant symptomatic focus, residual viable tumor, or focal progression. Further study into the benefits and sequencing of combining local therapy with systemic or targeted options will be helpful in the multi-disciplinary evaluation of this complex patient cohort.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149301433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment Options After Recurrence Following Perioperative Durvalumab Plus FLOT for Gastric and Gastroesophageal Junction Adenocarcinoma: A Biology-First Sequencing Framework. Durvalumab加FLOT治疗胃和胃食管交界处腺癌围手术期复发后的治疗选择:生物学优先测序框架。
IF 5.8 2区 医学
Current Treatment Options in Oncology Pub Date : 2026-10-28 DOI: 10.1007/s11864-026-01416-x
Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa
{"title":"Treatment Options After Recurrence Following Perioperative Durvalumab Plus FLOT for Gastric and Gastroesophageal Junction Adenocarcinoma: A Biology-First Sequencing Framework.","authors":"Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa","doi":"10.1007/s11864-026-01416-x","DOIUrl":"10.1007/s11864-026-01416-x","url":null,"abstract":"<p><strong>Opinion statement: </strong>Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) has established a new curative-intent standard for resectable gastric and gastroesophageal junction adenocarcinoma. Recurrence after this regimen creates a clinically distinct, pre-exposed metastatic state for which no prospective sequencing standard exists. Because direct post-D-FLOT evidence is absent, treatment decisions should distinguish exposure-analogous evidence from extrapolation from conventional metastatic trials. In practice, we first determine whether recurrence after perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is potentially amenable to local treatment and, if systemic therapy is required, document the recurrence phase, the dates of the last FLOT and durvalumab doses, prior radiographic and pathological response, residual neuropathy, immune-related adverse events, organ function, performance status, and disease tempo. We then obtain recurrent-tumor tissue when feasible and reassess human epidermal growth factor receptor 2 (HER2), claudin 18.2 (CLDN18.2), and microsatellite instability/mismatch repair status; programmed death-ligand 1 results are interpreted in the context of assay differences and prior durvalumab exposure. If HER2 is positive and no prior HER2-directed therapy was given, we prioritize a HER2-directed strategy. If CLDN18.2 is positive and HER2 negative, zolbetuximab-based therapy is reasonable when oxaliplatin re-use is clinically defensible, but very early relapse or persistent neuropathy should favor an alternative strategy or a clinical trial. Microsatellite instability-high or mismatch repair-deficient disease remains immunologically compelling, although checkpoint-inhibitor re-use after durvalumab is not established. In biomarker-negative disease recurring during treatment or within about 6 months, we favor a non-cross-resistant approach, using ramucirumab- or irinotecan-based therapy according to prior taxane exposure, neuropathy, and regional availability. With a longer treatment-free interval and recovered toxicity, selective fluoropyrimidine/platinum reintroduction becomes more reasonable. We avoid routine checkpoint-inhibitor rechallenge solely because programmed death-ligand 1 is positive. For trial eligibility and line-of-therapy nomenclature, we count recurrence within 12 months of the last administered perioperative systemic dose (chemotherapy or durvalumab, whichever was later) as one prior systemic line, while recognizing that this is a pragmatic classification rather than a validated biologic cutoff.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149301630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Personalized Therapy with Mercaptopurine in Acute Lymphoblastic Leukemia: Current Advances and Challenges. 巯基嘌呤治疗急性淋巴细胞白血病:目前的进展和挑战。
IF 5.8 2区 医学
Current Treatment Options in Oncology Pub Date : 2026-10-06 DOI: 10.1007/s11864-026-01415-y
Haoping He, Bowei Chen, Xiaoqiang Hao, Haoyue Li, Jia Du, Weiwei Liu, Aijun Zhang
{"title":"Personalized Therapy with Mercaptopurine in Acute Lymphoblastic Leukemia: Current Advances and Challenges.","authors":"Haoping He, Bowei Chen, Xiaoqiang Hao, Haoyue Li, Jia Du, Weiwei Liu, Aijun Zhang","doi":"10.1007/s11864-026-01415-y","DOIUrl":"10.1007/s11864-026-01415-y","url":null,"abstract":"<p><strong>Opinion statement: </strong>Mercaptopurine (6-MP) is a cornerstone drug for acute lymphoblastic leukemia (ALL) maintenance therapy. As a prodrug and purine analog, 6-MP is converted into the active cytotoxic product through a series of metabolic processes in the body. Its cytotoxic effects are mediated by the overactivation of deoxyribonucleic acid (DNA) mismatch repair mechanisms. The metabolism of 6-MP is influenced by multiple enzymes, and genetic polymorphisms encoding these enzymes affect drug tolerance and adverse reactions. Owing to significant individual variability, therapeutic drug monitoring (TDM) during 6-MP therapy has gained increasing attention, although no consensus has yet been established. Therefore, optimizing 6-MP maintenance regimens to mitigate adverse reactions and increase efficacy during this phase is critically important. Currently viable strategies include thiopurine enhanced ALL therapy (TEAM) and combination therapy with allopurinol. Finally, the issue of 6-MP resistance is attracting attention. Identifying methods for early detection of acquired resistance and developing corresponding strategies is important for improving the prognosis of ALL patients.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic Options for Recurrent Abdominal Low-grade Well-differentiated Liposarcoma. 复发性腹部低级别高分化脂肪肉瘤的系统选择。
IF 5.8 2区 医学
Current Treatment Options in Oncology Pub Date : 2026-09-30 DOI: 10.1007/s11864-026-01414-z
Anna Boulouta, Antonia Digklia, Anastasia Stergioula, Anastasios Kyriazoglou
{"title":"Systemic Options for Recurrent Abdominal Low-grade Well-differentiated Liposarcoma.","authors":"Anna Boulouta, Antonia Digklia, Anastasia Stergioula, Anastasios Kyriazoglou","doi":"10.1007/s11864-026-01414-z","DOIUrl":"10.1007/s11864-026-01414-z","url":null,"abstract":"<p><strong>Opinion statement: </strong>Well-differentiated liposarcoma (WDLPS) is a low-grade malignancy characterized by an indolent clinical course and a strong tendency for local recurrence. Unlike other sarcoma subtypes, pure WDLPS has a very low metastatic potential. However, in the course of the disease, dedifferentiation may occur and is associated with a substantially higher risk of metastases and mortality. Surgery remains the cornerstone of treatment for both primary and recurrent abdominal WDLPS, when a complete resection is possible. The role of systemic therapy in WDLPS is less clearly defined. Conventional cytotoxic chemotherapy generally has limited activity in pure WDLPS, and most clinical trials have included both WDLPS with dedifferentiated liposarcoma (DDLPS) or other liposarcoma subtypes, making the data for pure WDLPS difficult to interpret. Therefore, in clinical practice, we consider systemic treatment for patients with unresectable, symptomatic disease and in cases of repeated recurrences in which further local treatment is not possible. For selected patients with indolent and asymptomatic disease, active surveillance remains an appropriate strategy. The recent development of treatments directed against molecular alterations in WDLPS, namely CDK4 and MDM2 amplifications, have opened up a new era in the systemic treatment of this disease. Among these, anti-CDK4 agent palbociclib has shown the most mature clinical evidence to date, including recent results of overall survival data. MDM2 inhibition and combinations targeting both CDK4 and MDM2 represent promising areas which are currently under investigation. Due to the rarity of WDLPS and the lack of evidence from prospective studies, enrollment in clinical trials should be prioritized whenever possible.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书